C12N 2799/02
As vector
Official title: as vector
C12N2799/02 (As vector) appears on 2,517 US grants and 3,619 published applications in this corpus.
Search patents in C12N- Granted patents
- 2,517
- Published applications
- 3,619
- Assignees
- 1,088
- Inventors
- 4,649
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1990 | 1 | 0 |
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 9 | 0 |
| 1996 | 17 | 0 |
| 1997 | 52 | 0 |
| 1998 | 112 | 0 |
| 1999 | 128 | 0 |
| 2000 | 129 | 0 |
| 2001 | 106 | 31 |
| 2002 | 154 | 323 |
| 2003 | 136 | 1105 |
| 2004 | 118 | 295 |
| 2005 | 122 | 275 |
| 2006 | 149 | 170 |
| 2007 | 191 | 171 |
| 2008 | 192 | 154 |
| 2009 | 126 | 169 |
| 2010 | 111 | 161 |
| 2011 | 90 | 123 |
| 2012 | 91 | 100 |
| 2013 | 71 | 93 |
| 2014 | 56 | 74 |
| 2015 | 56 | 54 |
| 2016 | 56 | 61 |
| 2017 | 48 | 64 |
| 2018 | 44 | 32 |
| 2019 | 26 | 43 |
| 2020 | 26 | 34 |
| 2021 | 25 | 23 |
| 2022 | 17 | 18 |
| 2023 | 15 | 12 |
| 2024 | 15 | 18 |
| 2025 | 15 | 10 |
| 2026 | 10 | 6 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Gene-therapy vectors for treating cardiomyopathy29 Sep 2026US 12,747,453 B2
- Gene-therapy vectors for treating cardiomyopathy22 Sep 2026US 12,742,181 B2
- Baculovirus expression vector4 Aug 2026US 12,697,381 B2Intervet Inc.
- Compositions and methods for the treatment of skin diseases16 Jun 2026US 12,655,447 B2Krystal Biotech, Inc.
- Immunomodulating gene therapy26 May 2026US 12,636,302 B2Duke University
- Hla class ii deficient cells, hla class i deficient cells capable of expressing hla class ii proteins, and uses thereof3 Sep 2026US 2026/0256896 A1University of Washington through its Center for Commercialization
- Compositions and methods for integration of viral vectors30 Jul 2026US 2026/0218237 A1Poseida Therapeutics, Inc.
- Further improved aav vectors produced in insect cells23 Jul 2026US 2026/0209798 A1uniQure IP B.V.
- Viral expression construct comprising a fibroblast growth factor (fgf21) coding sequence21 May 2026US 2026/0139021 A1Universitat Autonoma De Barcelona
- Combination cancer therapy14 May 2026US 2026/0131028 A1Delta Next-Gene, LLC
Most cited
By later US patents
- Polypeptide variants with altered effector function1,378US 6,737,056 B1Genentech, Inc. · 2004
- Inhibition of cell proliferation using antisense oligonucleotides753US 5,756,476 AThe United States of America as represented by the Department of Health and Human Services · 1998
- Polypeptide variants with altered effector function381US 7,371,826 B2Genentech, Inc. · 2008
- Polypeptide variants with altered effector function373US 7,332,581 B2Genentech, Inc. · 2008
- Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma287US 5,776,456 AIDEC Pharmaceuticals Corporation · 1998